Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Arrowhead Pharmaceuticals invents tiny genetic medicines that switch off the genes causing serious diseases.
Arrowhead Pharmaceuticals is a biotech company that makes a special kind of medicine designed to silence bad genes. Almost none of its money comes from selling drugs yet. Instead, its cash comes from partners — mostly big drugmakers like Takeda and Novartis — who pay Arrowhead upfront, in milestone payments, and in royalties to use its technology. Only one product is approved and sold for its own profit, and that just happened. The rest of the pipeline is still in testing. So think of Arrowhead less as a store selling products and more as an inventor renting out its ideas while waiting for its own bigger payday.
The science works like this: many diseases happen because a person's body makes a harmful protein, and that protein is built from instructions in a gene. Arrowhead designs tiny molecules that ride into the right organ and tell the cell to stop following those instructions. Its main trick is a sugar coating that acts like a delivery truck, carrying the medicine straight to the liver or lungs. Because of that, the same basic technology can be aimed at many different illnesses — a liver disease here, a lung disease there — which is why partners keep signing up. That partner money is the company's lifeline until its own drugs reach the market.
The big recent turning point is commercial. In 2025, the FDA approved Redemplo, Arrowhead's medicine for a rare condition called familial chylomicronemia syndrome, where people cannot properly break down fats in their blood. That makes it the company's first product it actually sells and profits from. Arrowhead was founded in 1989 and spent decades as a research shop with no sales. Now it is slowly becoming a real commercial business. It burns cash on research and does not pay a dividend, so any free cash it has goes right back into testing new drugs — making the whole story a bet on whether its genetic-silencing platform keeps producing winners.
Saved answer · last researched 11 Oct 2026